Several neoclerodanes, such as salvinorin A (1) and herkinorin (3), have recently been shown to possess opioid receptor activity in vitro and in vivo. To explore the structure-affinity relationships of this interesting class of compounds, we have synthesized a series of analogues from 1 isolated from SalVia diVinorum. Here, we report the semisynthesis of neoclerodane diterpenes and their structure-affinity relationships at opioid receptors. This work will allow the further development of novel opioid receptor ligands.
cinnamoyl chloride afforded 9a and 9b, respectively. The reaction of 7 with 2-bromo and 3-bromobenzoyl chloride afforded analogues 10a and 10b in 60 and 70% yield, respectively. Compound 10c was synthesized as described previously. 20 Similar conditions using 2-thiophenecarbonyl chloride afforded 10d in 60% yield. Finally, the reaction of 7 with benzenesulfonyl chloride and 4-methylbenzenesulfonyl chloride afforded 11a and 11b in 76 and 86% yield, respectively.
Biological Results. Analogues 8-11 were then evaluated for affinity at opioid receptors using methodology previously described (Table 1) . 21 As shown previously, 1 and 2 have approximately the same affinity and selectivity for κ receptors. 11 This indicated that perhaps chain length might not play an important role. To further explore the role of chain length, we synthesized chain-extended analogues 8a-8c. Increasing the chain length by one carbon (8a) had little effect on affinity for κORs compared to 2 (K i ) 4 nM vs K i ) 1.8 nM). This modification also had little effect on affinity for δORs (K i ) 6690 nM vs K i ) 4030 nM). However, affinity for µORs was increased (K i ) 520 nM vs K i > 1000 nM). The further extension of the carbon chain, 8b and 8c, generally decreased affinity for κORs compared to 8a (K i ) 15 nM and K i ) 70 nM vs K i ) 4 nM). The additional chain length had little effect on affinity for µ and δORs compared to 8a. The replacement of the acetoxy group in 1 with a 2-tert-butoxycarbonylaminoacetoxy group (8d) resulted in reduced affinity at κORs compared to 1 (K i ) 90 nM vs K i ) 1.9 nM). This is interesting given the observation that replacement of the acetoxy group in 1 with an 2-acetylaminoacetoxy group abolishes affinity for κORs (K i > 10 000 nM). 17 This difference is likely due to the different radioligands used ([ 3 H]-diprenorphine vs [ 125 I]IOXY) or the additional steric bulk of the tert-butoxycarbonyl moiety compared to the acetyl group.
Given the clear effects of chain length in the C-2 position on affinity for opioid receptors, we synthesized 9a and 9b, analogues of herkinorin 3. The introduction of a one carbon spacer between the carbonyl and phenyl ring (9a) led to a decrease in affinity at κORs compared to 3 (K i ) 290 nM vs K i ) 90 nM). This change also resulted in a 90-fold decrease in affinity for µORs (K i ) 1090 nM vs K i ) 12 nM). The addition of a second methylene unit (9b) increased affinity for µORs 4-fold compared to 9a (K i ) 280 nM vs K i ) 1090 nM). This modification also increased affinity for κORs (K i ) 180 nM vs K i ) 290 nM). Generally, however, increasing the spacer between the carbonyl and phenyl ring decreased affinity approximately 10-fold for δORs compared to 3. After probing the spacer between the carbonyl and phenyl ring in 3, we sought to explore the role of ring substitution on affinity and selectivity for opioid receptors. Introduction of a bromo group in the 2-position of the benzene ring in 3 (10a) had no effect on κOR affinity (K i ) 90 nM vs K i ) 90 nM). The 2-bromo group, however, decreased affinity for µORs 9-fold (K i ) 110 nM vs K i ) 12 nM). This modification decreased affinity for δORs compared to 3 (K i > 10 000 nM vs K i ) 1170 nM) and thereby increased selectivity for µ and κ receptors over δ receptors. Parallel effects were seen at all three opioid receptors with 3-bromo analogue 10b. The presence of a 4-bromo group (10c) decreased affinity for κORs 8-fold compared to 3 (K i ) 740 nM vs K i ) 90 nM). To our delight, this modification had no effect on µ or δOR affinity (K i ) 10 nM vs K i ) 12 nM and K i ) 1410 nM vs K i ) 1170 nM, respectively). This result however is in contrast to previous reports. A previous report indicated that 10c had no affinity (K i > 10 000 nM) for any opioid receptor. 20 Given the large difference seen in our assay, we sought to further confirm the absolute configuration of 10c using a single-crystal X-ray diffraction study. Structural analysis was carried out and the absolute stereochemistry of 10c was determined using the Flack parameter 22 and is as shown (Figure 1 ). Finally, the bioisosteric replacement of the benzene ring with a 2-thiophene (10d) was explored. Diterpene 10d reduced affinity for κORs 3-fold compared to 3 (K i ) 260 nM vs K i ) 90 nM). This change, however, had no effect on affinity for µ or δORs (K i ) 10 nM vs K i ) 12 nM and K i ) 1,380 nM vs K i ) 1170 nM, respectively).
Given our previous finding that introduction of an aromatic group to the C-2 position increased affinity for µ receptors, 11 we synthesized compounds 11a and 11b, analogues of WH-1-32 (4). It was envisoned that replacement of the mesylate in 4 with a benzenesulfonate (11a) would result in a compound with reduced affinity at κORs and enhanced affinity at µORs compared to 4. As expected, this structural change reduced affinity at κORs compared to 4 (K i ) 60 nM vs K i ) 2.3 nM). To our surprise, 11a had no affinity for µORs (K i > 10 000 nM). In addition, introduction of a 4-methyl group to 11a (11b) had no effect on κOR affinity (K i ) 50 nM vs K i ) 60 nM) and increased affinity for δORs (K i ) 3720 nM vs K i > 10 000 nM) compared to 11a. This change, however, increased affinity for µORs compared to 11a (K i ) 220 nM vs K i > 10 000 nM). These changes, however, are not parallel to the ester series. This indicates that the previous structure-activity relationships (SAR) may not be applicable to the sulfonate series. It also suggests that these two series are not binding in an identical manner at either the µOR or κOR.
In conclusion, we have synthesized a series of neoclerodane diterpenes (8-11) from 1 isolated from S. diVinorum. We have shown that chain length in the C-2 position generally decreases affinity for κORs and increases affinity to µORs. Substitution in the 4-position of the benzene ring in 3 is best tolerated. Furthermore, 3 and mesylate 4 appear to bind in a different manner at both the κOR and the µOR.
Experimental Section
General Experimental Procedures. Unless otherwise indicated, all reagents were purchased from commercial suppliers and were used without further purification. All melting points were determined on a Thomas-Hoover capillary melting apparatus and are uncorrected. The 1 H NMR and 13 C NMR spectra were recorded at 300 MHz on a Bruker Avance-300 spectrometer or on a Bruker AMX-600 spectrometer using CDCl3 as solvent, δ values in ppm (TMS as internal standard), and J (Hz) assignments of 1 H resonance coupling. Thin-layer chromatography (TLC) was performed on 0.25 mm Analtech GHLF silica gel plates. Spots on TLC were visualized with vanillin/H2SO4 in EtOH. Column chromatography was performed with silica gel (32-63 µm particle size) from Bodman Industries (Atlanta, GA). Elemental analyses were performed by Atlantic Microlabs, Norcross, GA. The systematic name for salvinorin A (1) is (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c]pyran-7-carboxylic acid methyl ester.
(2S,4aS,6aR,7R,9S,10aS,10bR)-9-(Butyryloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic Acid Methyl Ester (8a). A solution of 7 (60 mg, 0.15 mmol), butyryl chloride (75 µL, 0.72 mmol), and a catalytic amount of DMAP in CH 2Cl2 (40 mL) was stirred at room temperature for 12 h. The mixture was washed with 2 N HCl (2 × 30 mL), saturated NaHCO3 (2 × 20 mL), and saturated NaCl (30 mL). The organic extract was dried (Na2SO4) and filtered and the solvent removed in vacuo to give the crude product as a pale yellow oil. The crude product was purified by flash column chromatography (30-40% ethyl acetate/ hexanes) to afford 48 mg (68%) of 8a as a white solid: mp 158-160°C
; 1 H NMR (CDCl3) δ 1.00 (3H, t, J ) 7. Results from the X-ray analysis on 10c drawn from the experimentally determined coordinates with thermal parameters at 20% probability. 64.2, 72.2, 75.0, 108.6, 125.4, 139.7, 143.9, 171.4, 171.8, 173.0, 202.2; anal. C 65.58%, H 7.27%, O 27.21%, calcd for C26H34O8, C 65.81%, H 7.22%, O 26.97%.
(2S,4aS,6aR,7R,9S,10aS,10bR)-9-(Hexanoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic Acid Methyl Ester (8c)
. 8c was synthesized as described for 8a from 7 using hexanoyl chloride to afford 53 mg (70%) of 8c as a white solid: mp 82-85°C; 1 (30 mL), and the mixture was stirred for 4 days at room temperature. The mixture was diluted with CH2Cl2 (80 mL) and was washed sequentially with 2 N HCl (2 × 80 mL), 2 N NaOH (2 × 50 mL), and water (2 × 50 mL). The organic extract was dried (Na2SO4), filtered, and concentrated to give a yellowbrown oil. The crude product was purified by flash column chromatography (30% acetone/hexanes) to give 98 mg (58%) of 8d as a white foam: mp 124-127°C; 1 -6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic Acid Methyl Ester (9b). 9b was synthesized from 7 as described for 8a using hydrocinnamoyl chloride to afford 69 mg (63%) of 9b as a white solid: mp 155-158°C; 1 H NMR (CDCl3) δ 1.14 (3H, s); 1.47 (3H, s) ( 2S,4aS,6aR,7R,9S,10aS,10bR)-9-(2-Bromobenzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic Acid Methyl Ester (10a). 10a was synthesized as described for 8a from 7 using 2-bromobenzoyl chloride to afforded 70 mg (60%) of 10a as a white solid: mp 189-191°C; 2S,4aS,6aR,7R,9S,10aS,10bR)-9-(3-Bromobenzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic Acid Methyl Ester (10b). 10b was synthesized as described for 8a from 7 using 3-bromobenzoyl chloride to afford 75 mg (70%) of 10b as a white solid: mp 195-199°C; 1 3N (0.38 mL, 2.73 mmol), pyridine (0.22 mL, 2.73 mmol), and a catalytic amount of DMAP in CH2Cl2 (40 mL) was stirred at room temperature overnight. The mixture was diluted with CH2Cl2 (30 mL) and washed with 2 N HCl (2 × 30 mL), saturated NaHCO3 (2 × 30 mL), and water (40 mL). The organic extract was then dried (Na2-SO4), filtered, and concentrated to give an oil, which was purified by flash column chromatography (30-40% ethyl acetate/hexanes) to give 63 mg (60%) of 10d as a white solid: mp 143-145°C; 1 (2S,4aS,6aR,7R,9S,10aS,10bR)-9-(Benzenesulfonyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic Acid Methyl Ester (11a). A solution of 7 (100 mg, 0.26 mmol), benzenesulfonyl chloride (66 µL, 0.51 mmol), pyridine (0.23 mL, 2.74 mmol), and a catalytic amount of DMAP in CH 2Cl2 (30 mL) was stirred at room temperature overnight. The mixture was diluted with CH2Cl2 (40 mL) and washed sequentially with 2 N HCl (2 × 30 mL), saturated NaHCO3 (2 × 30 mL), and water (40 mL). The organic extract was dried (Na2SO4), filtered, and concentrated to an oil, which was purified by flash column chromatography (40% ethyl acetate/hexanes) to give 103 mg (76%) of 11a as a white solid: mp 157-159°C (dec); 1 
